Trade secrets - the forgotten IP right

ARTICLE SUMMARY

Trade secrets are an important component of any company’s intellectual property assets. They may even be the crown jewels of their portfolio - they just may not know it.  And even if they do know, sometimes an organisation’s internal processes are simply not robust enough to protect these valuable secrets.

authors
Related Services
Related Industries

Trade secrets are an important component of any company’s intellectual property assets. They may even be the crown jewels of their portfolio - they just may not know it. And even if they do know, sometimes an organisation’s internal processes are simply not robust enough to protect these valuable secrets.

A US-based study revealed the theft of trade secrets is estimated to cost between 1 and 3% of advanced economies’ gross domestic product.

While there is no denying the value of trade secrets, they are currently being under-utilised as a strategic commercial tool even in the most sophisticated companies.

In this article written for FMCG CEO, Sarah explains how to identify a trade secret and - most importantly - how to keep it.

You can read the full article here.

Related News

Combination therapies: IP considerations for synergistic biologic products

Combination therapies: IP considerations for synergistic biologic products

Perfect storm – four drivers behind the mRNA litigation wave

Perfect storm – four drivers behind the mRNA litigation wave

Patent landscape and freedom-to-operate analysis for RNA-based therapies: identifying IP risks early

Patent landscape and freedom-to-operate analysis for RNA-based therapies: identifying IP risks early

Kodak v FujiFilm: the Court of Appeal confirms UPC’s long-arm jurisdiction

Kodak v FujiFilm: the Court of Appeal confirms UPC’s long-arm jurisdiction

Comparing EPC Article 53(a) and US patent law in gene editing ethics

Comparing EPC Article 53(a) and US patent law in gene editing ethics

EPO Board of Appeal refers claim interpretation and added matter questions

EPO Board of Appeal refers claim interpretation and added matter questions

Creating an effective IP strategy for CAR-T

Creating an effective IP strategy for CAR-T

When is a synbio company a gene therapy company?

When is a synbio company a gene therapy company?

See All News